STOCK TITAN
  1. Home
  2. News
  3. DHR

Danaher Corp. - DHR STOCK NEWS

Welcome to our dedicated news page for Danaher (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Danaher's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Danaher's position in the market.

News
Danaher Completes Acquisition of Abcam
Rhea-AI Summary
Danaher Corporation (NYSE:DHR) has completed the acquisition of Abcam plc (NASDAQ:ABCM) for $24.00 per share in cash, making Abcam an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News
Danaher Announces Quarterly Dividend
Rhea-AI Summary
Danaher Corporation (NYSE: DHR) declares a regular quarterly cash dividend of $0.24 per share of its common stock, payable on January 26, 2024, to holders of record on December 29, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
dividends
-
News
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
Rhea-AI Summary
Abcam plc (Nasdaq: ABCM) has entered into a definitive agreement for its proposed acquisition by Danaher Corporation (NYSE: DHR) for $24.00 per share in cash. The Court has issued the Court Order sanctioning the Scheme, and the Transaction is expected to close on December 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
acquisition
News
Danaher to Present at Evercore ISI HealthCONx Conference
Rhea-AI Summary
Danaher Corporation (DHR) CEO Rainer M. Blair to Present at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences
-
News
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
Rhea-AI Summary
Abcam plc (Nasdaq: ABCM) has obtained all Identified Clearances required for its proposed acquisition by Danaher Corporation (NYSE: DHR) for $24.00 per share in cash. The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England and Wales and the satisfaction or waiver of certain other customary closing conditions. The Court Hearing to sanction the Scheme is scheduled to be held on December 4, 2023. An updated expected timetable of principal events is provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
acquisition
-
News
Shareholders of Abcam Approve Proposed Acquisition by Danaher
Rhea-AI Summary
Abcam shareholders have approved the proposed acquisition by Danaher Corporation. The transaction will involve Danaher acquiring all outstanding shares of Abcam for $24.00 per share in cash. The approval paves the way for a successful transition and the delivery of maximum value to shareholders, employees, and customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
acquisition
News
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
Rhea-AI Summary
Danaher Corporation appoints Christopher Riley as Executive Vice President of its Biotechnology business, effective January 1, 2024. Riley, currently Vice President and Group Executive of Danaher's Life Sciences company, has a strong track record of delivering results and will report to President and CEO Rainer Blair.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
management
-
News
Danaher Reports Third Quarter 2023 Results
Rhea-AI Summary
Danaher Corporation announces Q3 2023 results, with net earnings of $1.1 billion and revenues of $6.9 billion. Non-GAAP adjusted diluted net earnings per common share were $2.02. The company expects non-GAAP base business core revenue to be down mid-single digits YoY for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
earnings
-
News
Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine
Rhea-AI Summary
Integrated DNA Technologies (IDT) completes its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa, marking its entrance into the therapeutics space. The facility will produce cGMP cell and gene therapy reagents and support researchers in transitioning from the lab to therapeutic development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
News
Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher
Rhea-AI Summary
Abcam files investor presentation and letter to shareholders regarding proposed sale to Danaher Corporation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
Stock DHR logo
Danaher Corp.

NYSE:DHR

DHR Rankings

#58 Ranked by Market Cap
#3077 Ranked by Stock Gains
#1871 Ranked by Dividends

DHR Stock Data

177.69B
659.36M
10.76%
81.69%
0.86%
Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables
Manufacturing
Link
US
Washington

About DHR

Danaher Corporation is an American globally diversified conglomerate founded by brothers Stephen and Mitchell Rales in 1984. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services.